Promising psoriasis drug study for rare muscle disease pulled before start
NCT ID NCT07012057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test deucravacitinib, a drug already approved for psoriasis, in adults with hard-to-treat dermatomyositis (DM) or juvenile dermatomyositis (JDM). Participants would have taken a pill twice daily for 24 weeks, with clinic visits every 4 weeks. However, the study was withdrawn before enrolling anyone, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted immune drug calm rare muscle inflammation?
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- HIV drug repurposed to fight muscle inflammation
- Can a skin biopsy tell your doctor which treatment will work?
- New hope for rare muscle disease: baricitinib trial aims to cut steroid use
- Scientists probe hidden clot risks in autoimmune skin disorders